WAVE Life Sciences Ltd reaches 20-day high ahead of WVE-007 trial data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 08 Dec 25
Source: 4
WAVE Life Sciences Ltd's stock surged by 60.48%, reaching a 20-day high as anticipation builds for the interim data from the Phase 1 trial of WVE-007.
The company is set to announce interim results for WVE-007, an innovative treatment targeting obesity, on December 8, 2025. This trial is crucial as it assesses the safety and efficacy of the drug, which has shown promising results in preclinical studies.
Investors are closely watching this announcement, as positive results could significantly enhance the company's position in the obesity treatment market and lead to further developments in their RNA medicines pipeline.
Analyst Views on WVE
Wall Street analysts forecast WVE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WVE is 33.00 USD with a low forecast of 21.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
14 Buy
0 Hold
0 Sell
Strong Buy
Current: 12.730
Low
21.00
Averages
33.00
High
50.00
Current: 12.730
Low
21.00
Averages
33.00
High
50.00
About WVE
Wave Life Sciences Ltd. is a biotechnology company focused on unlocking the broad potential of ribonucleic acid (RNA) medicines to transform human health. The Company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. The Company’s diversified pipeline includes clinical programs in alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease, as well as several preclinical programs utilizing the Company’s broad RNA therapeutics toolkit. Its programs include WVE-006, SERPINA1 (AATD); WVE-007 (GalNAc), INHBE (Obesity); WVE-N531, Exon 53 (DMD), and WVE-003, mHTT (HD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
